Vosoritide
As of the edition of 20 October 2026, Vosoritide is a protein: marketed, first approved in 2021 (EU); acts on NPR2; US protection ends in 2035.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2026
- Kind
- Protein
- Brand name
- Voxzogo
- First approved
- 26 August 2021 (EU)
- Approvals on record
- 10 in 5 regions
- Holder of the most recent approval
- Amicus Therapeutics; 3 holders in all
- Registered trials
- 15, 0 stopped early
- Disease areas
- Inherited and neonatal; Bones, joints and muscles; Hormones; Heart and blood vessels; Skin and connective tissue; Nutrition and metabolism
US protection
US protection ends in 2035.
The last listed US drug-substance patent ends in 2035. The application that gives this date is held by Amicus Therapeutics.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product15 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 15 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Vosoritide.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| NPR2 | Atrial natriuretic peptide receptor 2 | P20594 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 11 | 2 | 9 | 0 |
| Phase 3 | 4 | 1 | 3 | 0 |
| All trials | 15 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Amicus Therapeutics | Applicant and Lead sponsor of trials | 2014 to now |